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Summary The short QT syndrome, a recently discovered ion channel disorder, combines short-
ened repolarization, a predisposition to atrial and ventricular ﬁbrillatory arrhythmias, and a risk
of sudden death. Few cases have been reported, but the prevalence may be underestimated.
This syndrome might account for some cases of unexplained ventricular ﬁbrillation in patients
with otherwise healthy hearts. Patients have abnormally short QT intervals and refractory peri-
ods, and atrial/ventricular ﬁbrillation can be triggered during investigations. Gain-of-function
mutations have been detected in three genes encoding potassium channels. Treatment is based
on deﬁbrillator implantation, sometimes as a preventive measure. Quinidine may be beneﬁcial
in certain cases.
© 2008 Elsevier Masson SAS. All rights reserved.MOTS CLÉS
Intervalle QT ;
Résumé Nouvelle canalopathie de découverte récente, le syndrome du QT court associe
raccourcissement de la repolarisation et propension aux arythmies ﬁbrillatoires atriales et
ventriculaires pouvant mener à la mort subite. À ce jour seul un nombre très limité de cas
∗ Corresponding author.
E-mail address: mauryjphil@hotmail.com (P. Maury).
1875-2136/$ — see front matter © 2008 Elsevier Masson SAS. All rights reserved.
doi:10.1016/j.acvd.2008.08.009
780
Syndrome du QT ;
court ;
Fibrillation
ventriculaire
idiopathique ;
Mort subite ;
Canalopathie
sur l’implantation d’un déﬁbrillateur, qui sera même proposé parfois à titre prophylactique.
Une alternative médicamenteuse pourrait être représentée par la quinidine dans certains
cas.
© 2008 Elsevier Masson SAS. All rights reserved.
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ach year in the United States and Europe, several hun-
red thousand people are victims of sudden death (SD). The
mmediate cause is usually ventricular ﬁbrillation (VF) [1,2].
hile most patients have a known or unknown underlying
rrhythmogenic cardiopathy at the time of the event, the
eart is considered ‘‘healthy’’ in 5 to 10% of cases [1,3],
eaning that no morphological anomalies are detected
ith the methods routinely used in clinical practice [3,4].
ver the last two decades a number of etiologies have
een identiﬁed, corresponding to apparently pure elec-
rical disorders related to hereditary disorders affecting
ertain ion channels that generate cellular action poten-
ials. These ion channel disorders disrupt cardiac rhythms
nd are capable, when combined with certain environmen-
al factors, of causing malignant ventricular arrhythmias
nd SD. These disorders comprise, in chronological order of
heir discovery, long QT syndrome, catecholaminergic poly-
orphic ventricular tachycardia, and Brugada’s syndrome.
ut some cases of VF in patients with apparently healthy
earts do not correspond to any of these electro-clinical
yndromes and are considered ‘‘idiopathic’’, reﬂecting
ur limited knowledge in this area [4]. Some cases are
robably associated with early repolarization, as recently
eported.
A few years ago another entity was discovered
associating shortened repolarization with a risk of SD by
F— further reducing the proportion of ‘‘idiopathic’’ cases
f VF.
istorical background
T prolongation has long been known to increase the risk of
D and overall cardiac mortality among patients with a vari-
ty of underlying etiologies. However, it is only in the early
990s that Holter recordings of more than 6500 patients sug-
ested that a shorter than normal QT interval could be
etrimental: the risk of SD at two years was more than dou-
led in patients with a mean QTC below 400ms or above
40ms [5]. The princeps description of three familial cases
f extremely short QT associated with paroxysmal atrial
brillation (AF), plus an isolated case with syncope and
D, was reported in 2000 by Ihor Gussak et al. [6]. These
uthors were the ﬁrst to postulate the existence of a new
yndrome combining consistent shortening of repolariza-
s
p
o
s
rion and electrical instability. Then in 2003, Gaita et al.
ublished a more thorough description of two unrelated
amilies with a history of SD spanning several generations.
hey found that seven members of these families had a
onsistently short QT interval associated with syncope, pal-
itations, AF and documented episodes of VF [7]. These
atients had short atrial and ventricular refractory peri-
ds, and VF could be induced in most of them. Other cases
ave since been reported, [8—14] retrospectively validat-
ng the existence of this new syndrome of cardiac rhythm
isorder.
iagnosis
he frequency of the QT interval should be between 60 and
5 per min [15] in the lead (often V2) in which the ampli-
ude of the T wave is largest and where the return to the
soelectric line is clearest, from the beginning of the QRS to
he junction between the tangent of the maximal descend-
ng slope of the T wave and the isoelectric line [16]. QT
nd QTC values of 300ms or less were noted in these ini-
ial descriptions of highly selected patients [6,7], associated
ith a, tall, sharp, ﬁne, positive and symmetrical T wave,
specially in the precordial leads (V2 to V4); the ST seg-
ent was virtually absent [15,17] and, consequently, the
nterval between the end of the T wave and the following P
ave was prolonged (Fig. 1 and 2). In a review of the ﬁrst
5 reported cases, the QTC was found to be below 320ms,
nd this value thus became the diagnostic cutoff [18]. In
he 29 patients studied to date, the QT interval has always
een below 320ms and the QTC always below 340ms, with
n acuminate and symmetrical T wave in most cases [16]
Table 1). In some published cases, however, the QT was
s high as 340ms and the QTC even higher [10,11]. If the
pper normal limit of the QT interval is now well known,
he lower limit has received far less attention. It can be
eﬁned as the mean minus two standard deviations of the
T interval in a normal population. Values of 330ms (310ms
n children) for the QT [19] and between 360 and 380ms
or the QTC have been proposed [20]. QT or QTC intervals
elow these values can therefore be considered abnormallyP. Maury et al.
a pu être répertorié, mais une sous-estimation de la prévalence réelle est possible, ce syn-
drome pouvant expliquer un certain nombre de ﬁbrillations ventriculaires inexpliquées sur
cœur par ailleurs sain. Les patients présentent des intervalles QT et des périodes réfrac-
taires anormalement courts, et des ﬁbrillations atriales ou ventriculaires sont déclenchables
lors des explorations. À ce jour des mutations sur trois gênes codant pour les canaux potas-
siques et entraînant des gains de fonction ont été découvertes. Le traitement actuel reposehort. Indeed, other studies show that 99% of the normal
opulation have a QTC interval greater than 360ms (men)
r greater than 370ms (women) [21,22] (Table 1). As in this
yndrome, the QT interval shows little shortening as heart
ate increases [15,17], QT correction with Bazett’s formula
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Figure 1. ECG pattern in a patient with a short QT interval. The
ST segment is reduced and the T wave is tall and sharp, especially in
the precordial leads. The QT is 240ms. Owing to the high frequency,
correction with Bazett’s formula is inappropriate. The QT repre-
Figure 2. ECG pattern in another patient with a short QT interval
from a different family. Here the QT interval appears at ﬁrst glance
to be less short than in the previous case (although measuring only
300ms) but the T wave is tall and sharp and the segment between
the end of the T wave and the following P wave is long. The cor-
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8sents 78% of the QT predicted at this frequency with Rautaharju’s
formula (see text).
should probably only be used for frequencies below 80 or
85 per min [15], as the QTC can appear falsely normal at
higher cardiac rates [18]. Identiﬁcation of this anomaly is
therefore dependent on the frequency. When the frequency
is consistently too rapid, the diagnosis can only be con-
ﬁrmed by ambulatory recordings during slower phases, or
based on the poor adaptation of the QT interval to the fre-
a
t
t
pected QT (Bazett’s formula) is 335ms. The QT represents 80% of
he predicted QT at this frequency, using Rautaharju’s formula (see
ext).
uency recorded on the Holter or during an exercise test
11,15,17,18]. One alternative is to use a formula based
n ECG recordings of several thousand healthy subjects,
hus allowing one to predict the ‘‘normal’’ value of the QT
nterval for a given frequency [23]. In this formula, the QT
nterval predicted by the frequency, QTP = 656/1 + heart-
ate/100, and a QT value below 88% of the QTP represents
he lower normal limit [23,24]. In early clinical reports,
nd in the 29 recently reported cases, the QT was below
0% of the QTP [16,18]. Even if this formula is practical
nd insensitive to excessively low or high frequencies, it is
oo early to judge its sensitivity or speciﬁcity when used
o diagnose or screen for the short QT syndrome. The mor-
hology of the T wave can also be very useful, as ample
782 P. Maury et al.
Table 1 Lower boundaries of the QT interval in the normal population, and successive cutoffs used to deﬁne a short QT.
QT interval QTC interval
Lower normal limit of the QT interval
Moss AJ, 1993 [19], Luo S 1994 [20] 330ms (children 310ms) 360-380ms
Vincent GM, 1992 [22] 360ms (M) — 370ms (F)
Deﬁnition of ‘‘short QT’’
Gussak I, 2000 [5], Gaita F, 2003 [7] <300ms <300ms
0ms
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Giustetto C, 2006 [16]
nd symmetrical T waves are observed in the right precor-
ial leads in about 50% of cases [15,17]. Some patients also
ave a spontaneously variable QT interval, sometimes with
ransient normalization of repolarization, further hindering
iagnosis and screening [14]. Before envisaging a diagnosis
f the short QT syndrome, all causes of transient QT short-
ning must of course be ruled out, such as hyperkalemia,
ypercalcemia, acidosis, digoxin therapy or overdose, fever,
achycardia, vagal or sympathetic hypertonia, and acute
schemia [7,15,18].
pidemiology
review of 29 cases has just been published, involving
ight families plus men sporadic cases (21men and eight
omen) [16]. Similar unpublished cases are known to other
eams, and not all cases of short QT are included in
his study, which comprises only cases associated with a
ersonal or family history of SD. The recently updated
uropean registry (Euroshort, rainer.schimpf@med.ma.uni-
eidelberg.de) contains 51 cases (47 affected — 36 males —
nd four probably affected, 17 families, ﬁve sporadic cases,
0 with sudden death/aborted sudden death, nine with syn-
ope, six with atrial ﬁbrillation, three with palpitations (two
ith premature ventricular beats), 19 asymptomatic, mean
ge at clinical presentation 29 years old) (C. Giustetto and R.
chimpf) but not all published cases are included. It is likely
hat the prevalence of this syndrome is far higher, and that
nly the most severe cases are currently detected. The num-
er of cases is likely to grow as cardiologists become more
amiliar with these ECG patterns and as better diagnostic
ools are developed. In addition, in view of the lessons drawn
rom genetic studies of the long QT syndrome, and especially
he existence of a subpopulation of subjects with rele-
ant mutations but a normal phenotype [22], it is probable
hat the real prevalence is strongly underestimated, even
hough there is a good genotype-phenotype correlation,
t least for some mutations (see below). However, recent
pidemiological studies showed no cases of QTC <335ms
mong 12,012 healthy subjects [25], no QTC <300ms among
06,432 hospitalized subjects [26], and only 11 cases (0.1%)
f QTC <320ms and 43 cases (0.4%) of QTC <340ms in a pop-
lation of 10,822middle-aged Finnish subjects [27], thus
ajor forms therefore remain exceptional. These studies
hallenge the poor prognosis associated with a short QT
nterval, at least when the latter is found incidentally dur-
ng routine screening of a large population [25,27]. Finally,
t is also likely that a number of cases of ‘‘idiopathic’’
t
l
r
q
i<320ms
<340ms
F in fact correspond to a latent or borderline short QT
yndrome. Indeed, the QTC interval of men with VF of
o apparent cause is signiﬁcantly shorter than that of the
ormal population [21], and a QT interval less 300ms is
ound retrospectively in 12% of survivors of ‘‘idiopathic’’
F [28].
linical aspects
ean age at diagnosis is about 30 years (4 to 80 years) [16].
atients with a short QT interval can be totally asymp-
omatic (38%) [16] or suffer syncope (24%, ﬁrst event in 14%
f cases) [16] or palpitations (31%) [16] due to paroxysmal
6] or permanent AF [10], with a rapid [16] or slow ven-
ricular rate [10,13] or ventricular premature beats (VPB)
16]. AF or ﬂutter is documented in 24% of cases [16], at
ll ages, including children and adolescents, [6,16,18] and
ven in utero [13]. AF is therefore frequent in the short
T syndrome, and this means that the QT interval should
lways be measured in patients with AF and an otherwise
ealthy heart [17], particularly young patients and those
ith a positive family history. The vital risk is due to SD
31% of cases [16]), the most frequent manifestation; SD
s also the ﬁrst manifestation in most cases [16,18], and
s secondary to VF in the few cases in which it could be
ocumented [7,9,14,18,29,30]. VF or polymorphic ventric-
lar tachycardia seems to be triggered by VPB with short
oupling (180 to 300ms [14,30]). Syncope and cardiocircu-
atory arrest can occur in the adrenergic phase [7,14] or at
est [11,30] and SD can sometimes even occur in both cir-
umstances within a given family [17]. Sudden death has
een reported at all ages (from the ﬁrst months of life to
ore than 60 years [7,16]). Mean age at the time of SD
r syncope is 35± 25 years (median 39 years), [17] and the
isk of arrythmias therefore seems to persist for life. The
revalence of SD appears high in the few documented fam-
lies, [15—17] but it is probably overestimated because of
recruitment bias (the ﬁrst cases were detected because
f this very high prevalence of SD) [15,17] and registra-
ion of patients with familial SD [16]. Late potentials are
bsent [7,11], heart rate variability appears normal [7],
nd Holter recording and effort tests show VPB (sometimes
requent) [7,8,11,14,16]. The QT interval is relatively cons-
ant, shortening only moderately on effort [7,11] and not
engthening during slow phases; the slope of the QT-heart
ate correlation is weak [31] and values at maximal fre-
uencies are near-normal [16]. The dispersion of the QT
nterval seems normal [7,11] or prolonged (>60ms) [28] and
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QFigure 3. Triggering of ventricular ﬁbrillation by programmed ven
and short couplings (S1—S2 200ms and S2—S3 150ms).
the interval between the peak and the end of the T wave
is lengthened [17,32]. Electrophysiological studies show
short atrial and ventricular refractory periods (<180ms),
regardless of the genotype [7,11,15,16,18]. Suprahissien
conduction disorders [11,13] and a low ventricular rate dur-
ing AF that accelerates little on effort [10] have also been
described. Episodes of sustained AF can be triggered by
a single extrastimulus [15]. Programmed ventricular stim-
ulation (two sites, two or three basic rates, up to three
extrastimuli, with coupling intervals below 200ms until the
refractory period [16]) reproducibly triggers VF in two thirds
of cases [16—18] (Fig. 3), whether or not the patient is
symptomatic, and sometimes rapid monomorphic ventricu-
lar tachycardia [7]. Simple manipulation of the catheters
in the right ventricle can frequently trigger VF, and this
seems to be characteristic of the short QT syndrome [18].
Negative ﬁndings, especially in resuscitated VF patients
[9] could be due to inadequately short couplings [16]. No
underlying cardiopathies are found, of course, even after
thorough investigations [16] including myocardial biopsy [9]
or autopsy [7].
Genetics
A few years after its initial description, like other hered-
itary cardiac arrhythmias, the short QT syndrome is already
showing marked genetic heterogeneity. While mutations
have been discovered in some families [15,17], none are
found in most cases [16]. Five missense mutations on
three genes coding for potassium channels, responsible
for repolarization and already implicated in some cases
of the long QT syndrome, have been found in familial and
sporadic cases. Two different mutations have been found on
HERG, leading to substitution of the same amino acid in IKr
channels (SQT1) [12,29], two different mutations leading to
substitutions in the KCNQ1 gene coding for IKs (SQT2); [9,13]
and a mutation by substitution on the KCNJ2 gene, coding
a
s
s
i
mar stimulation in the pulmonary infundibulum with two extrastimuli
or IK1 (SQT3), [8] were identiﬁed between 2004 and 2005
Table 2). These gain-of-function mutations of repolarizing
otassium currents force the transmembrane potential to
each negative values more quickly and therefore contribute
o earlier repolarization as well as a shortening of the action
otential of myocardial cells and, therefore, of the QT
nterval in the whole heart [8,9,29]. Other gain-of-function
utations have been found on the same genes in familial
F cases with a normal QT interval [33—35]. In the ﬁrst two
amilies in which a HERG mutation was found (SQT1) [29],
he mutation was present in all phenotypically affected sub-
ects and absent in all the others [15,29]; as a result, in the
ight of current data, the genotype-phenotype correlation
eems excellent, for these mutations at least. Transmis-
ion appears to occur in dominant mode, with marked
enetrance in documented families due to the numerous
D affecting men and women across several generations
7,16]. There are also de novo mutations [13] and sporadic
ases [16]. However, these mutations are not found in other
ases or families, and when one compares the number of
utations already identiﬁed and the number of cases with-
ut mutations with the number of patients/families tested,
he short QT syndrome seems to show marked genetic
eterogeneity. For example, no mutations were found in
ix of the eight families described in the recent review,
r in the two sporadic cases [16]. A genotype-phenotype
elationship can already be proposed, even if systematic
tudies of a larger number of patients will be necessary to
onﬁrm these initial hypotheses [17]. ‘‘Typical’’ patterns
ith a sharp and symmetrical T wave seem to be present
n case of SQT1 [7,12,16], while a less ample T wave with a
ormal aspect (although quite symmetrical and close to the
RS) is noted in SQT2 [9,13] and SQT3 is associated with
n asymmetrical sharp T wave with a normal ascending
lope but a very rapid descending slope and a slightly less
hort QT interval [8]. The T wave can be less characteristic
n non genotyped forms and in forms with no identiﬁed
utations [16]. There is also marked phenotypic variability
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ith respect to symptoms and arrhythmias, whatever the
enotype, with asymptomatic forms in SQT1 and SQT3;
F, syncope and/or SD in SQT1 and SQT2; and nocturnal
eizures and palpitations in SQT3. This broad phenotypic
ariability is also found in families who have not been
enotyped or in whom no mutations have been detected
14,16]. Furthermore, a given mutation can be associated
ith SD in one family and with only AF in another [12,29].
n the recent study of 29 patients, SD occurred in patients
oth with and without ample and symmetrical T waves [16].
rrhythmogenic mechanism in the short
T syndrome
ellular electrophysiology is physiologically variable
ecause ion channels are heterogeneously distributed [36].
or example, in the ventricular wall, subendocardial cells,
ubepicardial cells and medio-ventricular cells (M cells)
ave appreciably different action potentials and electro-
hysiological properties [36]. The summit of the T wave is
lassically considered to mark the end of the repolarization
hase in subepicardial cells, while cells with the longest
ction potential —M cells— have already completed their
epolarization at the end of the T wave. The difference
etween the summit and the end of the T wave could
eﬂect this transmural dispersion of repolarization and,
hus, the potential electrical instability of the ventricle
18,36]. Temporal transmural dispersion of repolarization is
een in physiological conditions but is exacerbated in some
athological conditions such as the long QT syndrome and
rugada’s syndrome [36]. This dispersion is also increased
n the short QT syndrome, [32] favoring reentry phenomena
hat could be initiated by a PVB with very short coupling
18]; this has effectively been found in the rare cases
f onset of spontaneous arrhythmia documented to date
14,30].
anagement
ith the exception of young children, the ﬁrst 29 regis-
ered patients were all proposed an implanted deﬁbrillator
f they had unexplained syncope, a personal history of SD,
r in case of induction of VF in an otherwise asymptomatic
ubject [16,18]. Fourteen patients have been implanted
16]. Despite a mean follow-up of 23months (9—49) [16]
e do not have enough experience to judge this approach.
D are sufﬁciently frequent in some registered families,
nd spontaneous VF was documented a few months after
mplantation in a non inducible subject with a positive
amily history, pointing to the existence of a risk that can-
ot be detected with current methods [18,30]. At present,
owever, none of the other implanted patients has had
ppropriate therapy or a severe arrhythmic event. The
redictive value of programmed ventricular stimulation is
oorly known but imperfect, with a sensitivity of about 50%
15,6,18,30]. Similarly, risk stratiﬁcation based on the QT
nterval is probably unreliable, given the very different clini-
al histories of families with the same mutations and similar
T intervals [12,15,18,29]. In the largest population stud-
ed to date, neither the QTC nor gender appeared to have
l
t
h
t
d
v
Q
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[
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[
[Short QT syndrome. Update on a recent entity
predictive value, but no ﬁrm conclusions can be drawn from
data obtained in such a small number of patients [16]. In
this speciﬁc setting, however, deﬁbrillator use raises the
possibility of overdetecting the ample early T wave, with a
risk of double counting and, therefore, inappropriate treat-
ment [36]. These cases of double counting are related to
a reduction in the intracardiac R wave or to an increase
in the amplitude of the T wave over time and are solved
by reprogramming certain sophisticated detection parame-
ters [15,18,36]. The use of truly bipolar leads, obtention of
an ample R wave and a weak T wave after implantation,
and regular monitoring of the relative amplitudes of the R
and T waves can help to prevent these phenomena [36].
An alternative solution in these cases could be to admin-
ister drugs that lengthen the repolarization phase [15,18].
Class 3 antiarrhythmic drugs do not appear to be effective
for this purpose, probably owing to a lesser sensitivity of
mutated potassium channels to IKR blockers such as ibutilide
and sotalol, possibly because of a reduction in channel afﬁn-
ity for antiarrhythmic drugs due to a reduction in channel
inactivation [24,29,31]. Amiodarone, a drug that blocks IKR
and IKS, does not lengthen the QT interval [14], especially
in case of HERG mutations (C. Giustetto, personal obser-
vation), but can prevent the recurrence of symptoms that
are apparently dependent on adrenergic tone [14]. No such
experience with beta-blockers has been reported. Class 1C
drugs have also been tested. Flecainide slightly prolongs the
QT interval and the refractory periods but does not always
prevent inductibility [7,18,24], while propafenone has been
successfully used for paroxysmal AF in some patients with
the short QT syndrome and HERG mutations, without, how-
ever, modifying the duration of ventricular repolarization
[12]. Only quinidine, in experimental and clinical stud-
ies, showed some efﬁcacy within the strict framework of
SQT1 with HERG mutations, by normalizing repolarization
even during effort, lengthening the refractory periods, and
preventing the induction of VF and the occurrence of spon-
taneous malignant arrhythmias during follow-up of the few
patients in whom it was ﬁrst tested then prescribed for long-
term therapy (750 to 1000mg/d) [10,24,31]. This appears
to be due to its supplementary action on other repolarizing
potassium currents (especially IKS) or to increased afﬁnity
for IKR when the canal is in the open conformation [24,31].
The sensitivity of IKR to quinidine and/or the afﬁnity of
the channel for this anti-arrhythmic drug would appear to
be less strongly modiﬁed by the mutation than in the case
of sotalol [18,31]. The place of this adjuvant treatment is
poorly documented, but it could be interesting in case of
SQT1 (after conﬁrming its efﬁcacy by exercise testing and
electrophysiological studies) [15], as well as for children,
cases where deﬁbrillator implantation is refused or con-
traindicated, treatment of AF, [18,24] and possibly in case
of electrical storm. Ten patients have been treated with
quinidine for a median of 29months (21—36months), with
no symptomatic AF and no ventricular arrhythmias [16].Conclusion
The recently described short QT syndrome combines short-
ening of repolarization and susceptibility to atrial and
ventricular arrhythmias, with a risk of SD. It adds to the
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ist of genetic electrical abnormalities responsible for ven-
ricular ﬁbrillation in patients with morphologically healthy
earts, and thereby reduces the proportion of cases of ven-
ricular ﬁbrillation that remain ‘‘idiopathic’’. If its current
eﬁnition involves a marked shortening of the QT inter-
al, it is very likely that less severe forms, with less short
T intervals, could explain some cases of ‘‘idiopathic’’
entricular ﬁbrillation. The lower normal limit of the QT
nterval remains to be deﬁned for screening and preven-
ion purposes, and new tools must be developed to diagnose
orderline forms.
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